Literature DB >> 27325976

Newer antiatherosclerosis treatment strategies.

Amitesh Aggarwal1, Safal Singh1.   

Abstract

Atherosclerosis has been a target of much clinical and molecular research. As a result of this extensive research, it is amply clear that atherogenesis is a multifactorial process involving an interplay of metabolic, immune and inflammatory mechanisms. Antiatherosclerotic strategies are today aiming for a multipronged approach targeting each arm of this multifactorial process. The newer agents under development can be divided into three broad categories: anti-inflammatory agents, modulators of intermediary metabolism and antiatherosclerosis vaccines. Potential targets for anti-inflammatory agents include inhibition of conversion of low-density lipoprotein (LDL) to oxidised LDL, blocking or downregulation of cell adhesion molecules, chemokine modulation and macrophage receptor blockade. Beyond inhibition of plaque formation, efforts are also ongoing to develop agents which stabilise the plaque by increasing its fibrous content and inhibiting its disruption. So far as research in the sphere of intermediary metabolism is concerned, the focus is now primarily on raising high-density lipoprotein and promoting reverse cholesterol transport; potential targets include cholesteryl ester transfer protein, liver X-receptor, lecithin cholesterol acyltransferase and high-density lipoprotein mimetics. Acyl-coenzymeA: cholesterol acyltransferase is another enzyme whose selective and differential inhibition is under active investigation. The concept of immunisation against a non-communicable disease such as atherosclerosis is still in its nascent stages. However, with increasing evidence to suggest the role of antigen-specific T-cell-mediated immunity in atherogenesis, this approach is potentially promising. Possible antigens under evaluation include oxidised LDL and its subparticles, heat-shock proteins and cholesteryl ester transfer protein. With cardiovascular disease being the single leading cause of death worldwide, the development of a safe and successful antiatherosclerosis strategy (possibly employing a combination of agents acting at various levels) will indeed be a major 21st-century achievement.

Entities:  

Keywords:  Antiatherosclerosis; atherosclerosis; newer; treatment

Year:  2011        PMID: 27325976      PMCID: PMC4898547          DOI: 10.1136/ha.2010.003129

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  38 in total

Review 1.  The role of adaptive T cell immunity in atherosclerosis.

Authors:  Ziad Mallat; Soraya Taleb; Hafid Ait-Oufella; Alain Tedgui
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

2.  Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions.

Authors:  Dror Harats; Niva Yacov; Boris Gilburd; Yehuda Shoenfeld; Jacob George
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

Review 3.  Dalcetrapib: a review of Phase II data.

Authors:  Jennifer G Robinson
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

4.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

5.  Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.

Authors:  Karine Oumouna-Benachour; Chetan P Hans; Yasuhiro Suzuki; Amarjit Naura; Rahul Datta; Souad Belmadani; Kenneth Fallon; Cooper Woods; A Hamid Boulares
Journal:  Circulation       Date:  2007-04-16       Impact factor: 29.690

Review 6.  Cytokines in atherosclerosis: pathogenic and regulatory pathways.

Authors:  Alain Tedgui; Ziad Mallat
Journal:  Physiol Rev       Date:  2006-04       Impact factor: 37.312

7.  EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.

Authors:  Sylvie Marleau; Diala Harb; Kim Bujold; Roberta Avallone; Khadija Iken; Yanfei Wang; Annie Demers; Martin G Sirois; Maria Febbraio; Roy L Silverstein; André Tremblay; Huy Ong
Journal:  FASEB J       Date:  2005-08-25       Impact factor: 5.191

Review 8.  New trends in anti-atherosclerotic agents.

Authors:  C Napoli; V Sica; O Pignalosa; F de Nigris
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 9.  Nutraceuticals and atherosclerosis: human trials.

Authors:  Lina Badimon; Gemma Vilahur; Teresa Padro
Journal:  Cardiovasc Ther       Date:  2010-08       Impact factor: 3.023

Review 10.  In search of antioxidants and anti-atherosclerotic agents from herbal medicines.

Authors:  Ming-Shi Shiao; Jing-Jing Chiu; Bao-Wen Chang; Jane Wang; Wei-Ping Jen; Ye-Jer Wu; Yuh-Lien Chen
Journal:  Biofactors       Date:  2008       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.